Getinge B stock trades around raised earnings consensus as price target climbs
Published on 08/25/2026 at 16:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Getinge AB's B stock (ISIN SE0000202624) is trading close to an upgraded analyst target on August 25, 2026, after the Swedish medtech group’s latest interim report prompted a notable reset in earnings expectations. Recent market data from a European quote overview shows the shares changing hands at 244.25 SEK in intraday trading on August 25, 2026, modestly lower by 0.31 percent on the day but up 12.11 percent since the start of 2026, underscoring how the post-results re-rating has supported the valuation. A separate consensus summary dated August 25, 2026 indicates that the average 12-month price target on the shares has moved higher to 245.09 SEK, which is essentially in line with an indicated spot price of 245.20 SEK and highlights how the market price now trades almost on top of the updated analyst view. Recent reporting on the interim results and the higher earnings consensus notes that the shares jumped on the day of the report and have continued to outperform the Swedish blue-chip index in the weeks since.
According to that August 25, 2026 consensus snapshot, Getinge B’s last indicated quote of 244.25 SEK reflects a gain of 16.2 percent since the publication of the latest interim report in July 2026, compared with a 5.7 percent advance for the OMXS30 index over the same span, underscoring an outperformance gap of 10.5 percentage points. The same overview points out that the stock’s last official closing price stood at 245.00 SEK, very close to the revised average price target of 245.09 SEK, which has been lifted from 228.08 SEK, representing a 7.5 percent upward adjustment that brings the target into line with the current share price zone. The same consensus overview emphasizes that this move in the target range follows an earnings release that led analysts to upgrade their profit forecasts, signalling a more constructive stance on the company’s margin and growth trajectory.
Consensus earnings move after July 2026 interim report
The trigger for the latest shift in sentiment was the publication of Getinge’s interim report in July 2026, which prompted analysts to revise their earnings estimates upward for the coming periods. While the detailed line items of the July 2026 interim report are not fully reproduced in the consensus summary, the reporting highlights that the company’s profitability metrics came in better than previously expected, leading to a higher projected earnings per share level in the forecast horizon. In the same context, the consensus dataset references a dividend figure for the current fiscal year, quoting an average projected dividend of 5.26 SEK per share versus 5.10 SEK in an earlier snapshot, implying growth of 3.1 percent and pointing to the expectation that the company will continue to distribute a modestly higher cash return to shareholders in the current year.
The July 2026 interim release also marked an inflection in share-price performance. The consensus report indicates that Getinge B gained 10.1 percent on the day the results were published, underscoring that the figures and guidance were welcomed by the market. The subsequent 16.2 percent rise in the shares from the report date to August 25, 2026, compared with a 5.7 percent move in the OMXS30 index, means the stock has outpaced the Swedish large-cap benchmark by more than 10 percentage points since the publication of the interim figures, a magnitude of relative strength that investors often read as confirmation that new information has altered the perceived earnings trajectory. For a medtech issuer that must balance capital spending on innovation with profitability, such a post-results rally suggests that investors see scope for both margin improvements and sustainable top-line growth.
Valuation, price target alignment and dividend context
At the current share price area around 244–245 SEK as of August 25, 2026, Getinge B trades almost exactly in line with the updated average price target of 245.09 SEK that analysts have assigned following the July 2026 report, according to the consensus overview. The fact that the price target has been increased from 228.08 SEK to 245.09 SEK, a rise of 7.5 percent, while the stock itself has appreciated 16.2 percent since the report date, indicates that the market has moved faster than analysts’ target revisions, pulling the share price up to the new target band in the weeks after the numbers were released. This kind of alignment between the spot price and the average target can sometimes signal a period of consolidation, as further upside would likely require either additional upward revisions to earnings forecasts or new operational catalysts that justify a richer multiple.
The same consensus snapshot’s dividend line provides another anchor point for valuation discussions. The projected average dividend of 5.26 SEK per share for the current fiscal year, compared with an earlier 5.10 SEK forecast, corresponds to a projected dividend growth rate of 3.1 percent and offers a modest yield when set against a share price of around 245 SEK. For investors, this indicates that a portion of expected shareholder return is meant to come from ongoing income, while the balance is driven by capital appreciation tied to earnings growth and potential margin expansion. The fact that the dividend projection has been nudged higher alongside the earnings consensus suggests that analysts see room for the company to support both investment and shareholder distributions without unduly stressing its balance sheet.
The performance context relative to the OMXS30 also matters for portfolio allocation decisions. With Getinge B up 16.2 percent since the release of the July 2026 interim report, versus 5.7 percent for the large-cap index, the stock’s outperformance gap of 10.5 percentage points means that it has contributed disproportionately to any benchmark-aware portfolio that holds it at index weight or above. For active managers, such an outperformance streak raises the question of whether the valuation is now full at the current price-target-aligned level or whether further estimate upgrades could extend the trend. The consensus data indicate that the market’s post-report enthusiasm has already been reflected in both the higher target and the bigger price move, leaving the forthcoming quarterly update as the next key test of whether current expectations are sustainable.
Getinge’s medtech portfolio and hospital solutions
Getinge AB operates as a global provider of medical technology and life science equipment, with its B shares representing the most widely traded class on the Stockholm exchange. The group’s portfolio spans products and solutions that support acute care, surgery, and intensive care, as well as sterile reprocessing and life science applications. One emblematic product line for the company is its range of advanced ventilators and anesthesia systems used in intensive care units and operating theaters, which are designed to deliver precise respiratory support and monitoring for critically ill patients. These systems integrate with hospital information networks and decision-support software, enabling clinicians to track ventilation parameters in real time and adjust treatment protocols to match patient needs.
In addition to respiratory care, Getinge supplies operating room tables, lights, and visualization systems that help surgical teams manage complex procedures more efficiently, as well as sterilization and disinfection equipment that underpin infection-prevention strategies in hospitals and laboratories. The life science segment provides sterilizers, washers, and isolation systems for pharmaceutical and biotech production environments, where contamination control is paramount. Together, these product families create a comprehensive offering targeting the full workflow of patient treatment, from admission through surgery to intensive care and discharge. For investors, the breadth of this portfolio provides a diversified revenue base that can mitigate cyclical swings in any single product category, while the need for ongoing replacement and service supports recurring revenue streams.
Getinge B stock and recent trading levels
In recent trading on August 25, 2026, a real-time quote view for Getinge B linked to the Cboe Europe venue showed a last price of 244.25 SEK, down 0.31 percent on the session but higher by 1.95 percent over the preceding five trading days and ahead by 12.11 percent since January 1, 2026, underscoring a solid year-to-date performance for the shares. The same data table identifies 245.00 SEK as the most recent official closing price, reinforcing that the stock currently oscillates in a narrow band around the 245 SEK level in the wake of the consensus target revision. While the precise 52-week high and low are not enumerated in the consensus summary, the fact that the shares now trade within a fraction of the revised average price target of 245.09 SEK suggests that they are at the upper end of their recent trading range, a level at which many investors reassess risk-reward dynamics.
Getinge B is listed on the Stockholm exchange and reflects the market’s evolving view of the company’s earnings power and strategic execution in the global medtech landscape. Given the post-interim-report performance, the key watchpoints for holders of the stock over the coming quarters will be whether the company can sustain margin improvements, deliver on revenue growth ambitions in both developed and emerging markets, and continue to manage regulatory and quality-related risks effectively. As of the most recent close quoted on August 25, 2026, the stock’s proximity to the updated consensus target indicates that the market has already priced in a significant portion of the expected earnings uplift, leaving upcoming financial disclosures and any strategic updates as critical catalysts for the next leg of performance.
Read more
Hospital ventilators as a flagship product
Among Getinge’s diverse product lines, the company’s advanced intensive care ventilators stand out as a flagship offering that illustrates how its technology directly supports modern hospital workflows. These ventilators are designed to deliver highly controlled respiratory support for patients in critical condition, with features that allow clinicians to tailor ventilation modes, monitor lung mechanics, and adjust parameters in real time based on individual patient responses. In many installations, the ventilators are integrated into broader patient-monitoring systems and hospital IT networks, enabling data from the ventilator to feed into electronic medical records and decision-support algorithms that guide treatment choices.
The strategic importance of this ventilator portfolio is twofold. First, it addresses a core clinical need in intensive care units where demand for reliable, configurable, and easy-to-service devices is high and recurring, leading to a combination of equipment sales and aftermarket service contracts. Second, the installed base generates opportunities for software and connectivity upgrades, as hospitals seek to enhance monitoring capabilities and integrate devices into digital platforms that improve patient safety and workflow efficiency. For a company whose shares have rallied in response to improved earnings expectations and an upgraded price target, the strength and resilience of such core product lines are central to the market’s willingness to assign a premium valuation multiple to future profit streams.
Stock valuation snapshot as of late August 2026
As of the close reported for August 25, 2026, Getinge B trades on the Stockholm exchange at 245.00 SEK per share, according to the same consensus-linked quote overview that lists 245.00 SEK as the latest closing price. With the stock up 16.2 percent since the July 2026 interim report and ahead by 12.11 percent since the start of 2026, the shares now sit at a level that is in line with the updated average price target of 245.09 SEK. Against this backdrop, the projected dividend of 5.26 SEK per share for the current fiscal year points to a modest forward dividend yield when measured against the current price, while the 3.1 percent increase compared with the earlier 5.10 SEK forecast signals an expectation of continued incremental shareholder returns. For investors, this combination of upgraded earnings consensus, an aligned price target, and a gradually rising dividend forms the core of the current Getinge B stock thesis in late August 2026.
Fact box
Company: Getinge AB
ISIN: SE0000202624
Ticker: GETI B
Exchange: Stockholm
Price (as of August 25, 2026, 2:35 p.m. CET): 244.25 SEK
Market cap: not specified in available data
Sector / Industry: Medical technology / health care equipment
